Vitamin E for the treatment of cardiovascular disease - Is there a future?

被引:23
作者
Violi, F
Cangemi, R
Sabatino, G
Pignatelli, P
机构
[1] Univ Roma La Sapienza, Dept Expt Med & Pathol, Div Clin Med 4, I-00161 Rome, Italy
[2] Univ Chieti G DAnnunzio, Chieti, Italy
来源
VITAMIN E AND HEALTH | 2004年 / 1031卷
关键词
oxidative stress; atherosclerosis; vitamin E; antioxidant; cardiovascular disease;
D O I
10.1196/annals.1331.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxidative stress seems to play a key role in the pathogenesis of atherosclerosis. Agents that protect low-density lipoprotein from oxidation have been shown in a range of in vitro and animal models to reduce the development and progression of atherosclerosis. These agents include antioxidant micronutrients such as vitamin E. They have gained wide interest because of the potential for prevention of atherosclerotic vascular disease in humans. In the last decade, many trials with antioxidants have been carried out in patients with cardiovascular disease, but the results are equivocal. The reason for the disappointing findings is unclear, but one possible explanation is the lack of identification criteria of patients who are potential candidates for antioxidant treatment. This review analyses the data reported so far to determine whether they clearly support the premise that patients at risk of cardiovascular disease may be candidates for antioxidant treatment.
引用
收藏
页码:292 / 304
页数:13
相关论文
共 55 条
[1]   Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis [J].
Boaz, M ;
Matas, Z ;
Biro, A ;
Katzir, Z ;
Green, M ;
Fainaru, M ;
Smetana, S .
KIDNEY INTERNATIONAL, 1999, 56 (03) :1078-1083
[2]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[3]   Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers [J].
Carroll, MF ;
Schade, DS .
CIRCULATION, 2003, 108 (01) :24-31
[4]  
Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5
[5]  
Cosentino F, 1997, CIRCULATION, V96, P25
[6]  
DAVIS PJ, 1997, CONT ENDOCRINOL, V2, P17
[7]   Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects -: No further effect of vitamin E [J].
De Caterina, R ;
Cipollone, F ;
Filardo, FP ;
Zimarino, M ;
Bernini, W ;
Lazzerini, G ;
Bucciarelli, T ;
Falco, A ;
Marchesani, P ;
Muraro, R ;
Mezzetti, A ;
Ciabattoni, G .
CIRCULATION, 2002, 106 (20) :2543-2549
[8]   Progression of carotid intima-media thickness and plasma antioxidants: The Los Angeles Atherosclerosis Study [J].
Dwyer, JH ;
Paul-Labrador, MJ ;
Fan, J ;
Shircore, AM ;
Bairey, CN ;
Dwyer, KM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (02) :313-319
[9]   Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial [J].
Fang, JC ;
Kinlay, S ;
Beltrame, J ;
Hikiti, H ;
Wainstein, M ;
Behrendt, D ;
Suh, J ;
Frei, B ;
Mudge, GH ;
Selwyn, AP ;
Ganz, P .
LANCET, 2002, 359 (9312) :1108-1113
[10]  
Feki M, 2000, CLIN CHEM, V46, P1401